Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that more research is needed to reduce frequent hospital visits, addiction medicine education improves with specific training, early breast cancer surgery findings are emerging, nipple smears are not very accurate, surgery for older melanoma patients doesn't extend life, a genetic condition in infants can often be treated with one drug, doctors are inconsistent with blood clot medication, a certain gene may protect against cell damage, muscle gene overexpression affects many other genes, and some mitochondrial genes are less active in mice with tumors.

PRP and cell therapies may help with hair loss, but more research is needed.

Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

ADSC-CM treatment improved hair density and thickness in women with hair loss, safely and effectively.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Five preservatives may disrupt hormone function and need more health and environmental risk assessment.

Valproate can cause hair loss and changes in hair appearance, but may help regrow hair when applied topically.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Long-term high testosterone levels can improve bone density and reduce body fat but may increase the risk of prostate cancer and high blood pressure.

Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.

Using platelet-rich plasma, basic fibroblast growth factor, and minoxidil together significantly increases hair count and growth rate in people with hair loss.

High-dose vitamin A and E with zinc improved blood sugar control and insulin function in diabetics, but may cause hair loss.

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

Inactive stem cells in hair follicles and muscles can avoid detection by the immune system.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Micrografts improve hair density and thickness without side effects.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

High potency topical steroids are the most effective treatment for pediatric alopecia areata.

Upadacitinib may effectively treat alopecia areata without side effects.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Regenerative medicine is effective and safe for treating vitiligo.

New and existing treatments for hair loss show promise, with some being more effective for men and others for women.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.